Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITV-1
- Development stage
- Unknown
- Lead developer
- Virogentics
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ITV-1 is a therapeutic vaccine and immunomodulator composed of inactivated pepsin fraction (IPF), a purified extract derived from porcine pepsin. It is developed primarily for the treatment of HIV/AIDS and has also been investigated for other indications such as hepatitis C and immune system modulation. The drug acts as an inhibitor of the HIV envelope proteins gp120 and gp41, functioning as both a fusion inhibitor—blocking viral entry into host cells—and an immunostimulant that enhances immune cell activity. Clinical trials have demonstrated improvements in immune indices (including CD3 T, CD4 T, CD8 T cells), reductions in viral load to undetectable levels in some patients, beneficial effects on opportunistic infections associated with AIDS, good compatibility with antiretroviral drugs, and minimal side effects. ITV-1 has also shown potential benefits in other diseases characterized by immune dysfunction or chronic infection[1][2][5][6][7].
- Brand names
- ImmunH
- Other names
- Immune Therapeutic Vaccine-1Inactivated pepsin fraction HIV vaccineIrreversible pepsin fraction HIV vaccine
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on ITV-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITV-1.